News
Drugmaker Refuses FDA's Request to Pull Gene Therapy Tied to Patient Deaths
The agency also revoked Sarepta's platform technology designation for AAVrh74 Friday and issued a safety communication saying the agency was investigating the three deaths due to acute liver failure following treatment with Sarepta's AAVrh74 gene therapies.
MedPage Today on MSN22h
Gene Therapy May Hold Better Outcomes for Congenital Deafness Than Cochlear ImplantAt just 3 months of follow-up, gene therapy participants had comparable auditory and speech perception with cochlear ...
Sarepta Therapeutics said on Monday it will pause all shipments of Elevidys in the United States after two teenage boys with a rare condition called Duchenne muscular dystrophy, who had received the ...
Sarepta Therapeutics has paused U.S. shipments of its gene therapy Elevidys after two teenagers with Duchenne muscular ...
A team of Chinese medical experts say they can produce anti-cancer cells directly inside the human body using gene therapy ...
Massachusetts-based Sarepta Therapeutics, facing scrutiny from regulators, is reducing its global workforce by 36% in an ...
Our Bureau, Mumbai Friday, July 18, 2025, 17:45 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback